Trial · NCT06619015
Tailoring Obesity Treatment Trial
NCT06619015, Phase 2, Phase 3, Withdrawn, Esbjerg Hospital - University Hospital of Southern Denmark
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tailoring Obesity Treatment Trial. Trials, record NCT06619015. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06619015
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tailoring Obesity Treatment Trial
- NCT number
- NCT06619015
- Status
- Withdrawn
- Phases
- Phase 2, Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
- Conditions
- Obesity, Appetite Regulation, PreDiabetes
- Interventions
- Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj
- First posted
- 2024-10-01
- Last updated
- 2026-04-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in kilocalorie (kCal) consumption at ad libitum meal test, from baseline, to after 26 weeks of semaglutide of which the last two weeks is with the addition of either pramlintide or placebo | From baseline at the start of the study(week 0), to the end of the study after 26 weeks | |
| Secondary | Difference in total weight loss between the subgroups (Obesity phenotypes) | From baseline (week 0) to end of study (week 26) | |
| Secondary | Change in appetite and satiety sensations as measured by Visual Analog Scale (VAS) prior to and following the meal tests | From baseline(week 0) to after 24 weeks, and to the end of the study(week 26) | The meal test will be performed at baseline, after 24 weeks and at the end of the study(week 26). Prior to and following the meal tests a VAS measuring appetite and satiety sensation will be answered. |
| Secondary | Change in gastric emptying rate assessed by paracetamol (acetaminophen) test | From baseline (week 0) to end of study(week 26) | The gastric emptying test will be performed at baseline (week 0) and at the end of the study (week26). |
| Secondary | Total weight loss | From baseline(week 0) to after 24 weeks, and to the end of the study(week 26) | Total weight loss from baseline, after 24 weeks, and at the end of the study( week 26) The results will be repoted as percentage (%) weight loss. |
| Secondary | Total weight loss | From baseline(week 0) to after 24 weeks, and to the end of the study(week 26) | Total weight loss from baseline, after 24 weeks, and at the end of the study( week 26) The results will be repoted as total weight loss in Kg |
| Other | Change in sensory specific desires as measured by a taste test | From baseline (week 0) to after 24 weeks, and to the end of the study (week 26) | The taste test will be performed at baseline, after 24 weeks, and at the end of the study (week 26) |
| Other | Change in hedonic eating behavior as measured by questionnaires | From baseline (week 0) to after 24 weeks, and to the end of the study (week 26) | The questionnaires; Food pleasure scale, Yale Food Addiction Scale 2.0, Dutch Eating Behavior Questionnaire and The Eating Disorder Quality of Life Scale questionnaires will assess hedonic, emotional and binge- eating patterns and eating related quality of life. The questionnaires will be answered at baseline(weeks 0) , after 24 weeks and at the end of the study (week 26) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06619015
GET https://conductscience.org/api/trials/v1/NCT06619015/registered